Reliability and validity of the French adaptation of the Family Relationship Index–short form in patients’ with chronic kidney disease-Reference-Cited by-同舟云学术

Reliability and validity of the French adaptation of the Family Relationship Index–short form in patients’ with chronic kidney disease

Published:2020-08-10 Issue:1 Volume:27 Page:166-175
ISSN:1359-1053
Container-title:Journal of Health Psychology
language:en
Short-container-title:J Health Psychol

Author:

Montalescot Lucile¹^ORCID,Speyer Elodie²^ORCID,Legrand Karine³,Ayav Carole³,Combe Christian⁴,Stengel Bénédicte²,Untas Aurélie¹

Affiliation:

1. Université de Paris, LPPS, Boulogne-Billancourt, France

2. Université Paris-Saclay, Université Versailles Saint-Quentin-en-Yvelines, Université Paris-Sud, Inserm, Équipe Epidémiologie Clinique, CESP, Villejuif, France

3. Epidémiologie Clinique, Inserm CIC-EC, CHU de Nancy, Vandoeuvre-lès-Nancy, France

4. Service de Néphrologie Transplantation Dialyse Aphérèses, Centre Hospitalier Universitaire de Bordeaux, and Unité INSERM U1026, Bordeaux, France

Abstract

The Family Relationship Index (FRI) measures family cohesion, expressiveness and conflict. This study aimed to investigate its reliability and validity in patients with chronic kidney disease (CKD). Confirmatory factor analysis was performed on 1657 patients and on subgroups according to socio-demographics and medical variables. Two items with poor saturation were excluded. The indexes indicated an acceptable fit. Reliability was especially weak for expressiveness. Our results provide partial support for the use of the French-version of the FRI in patients with advanced CKD. The family relationship index should be used with caution, especially in certain subgroups and for the expressiveness subscale.

Funder

Fresenius Medical Care

AstraZeneca

Baxter International

Vifor Fresenius

Agence Nationale de la Recherche

Lilly France

GlaxoSmithKline

Sanofi-Genzyme

Merck Sharp and Dohme

Otsuka Pharmaceutical

Amgen